Company Intelligence
3SBio
三生制药
HK: 1530Shenyang, Liaoning, ChinaFounded 1993
BIOSECURE
No Known BCC Exposure
3SBio is a drug innovator, not a CDMO/CRO. No BIOSECURE exposure. No 1260H listing.
1
Tracked Deals
3
Therapeutic Areas
3
Modalities
Overview
3SBio (三生制药) is a Chinese biopharmaceutical company that achieved one of the highest upfront-to-total ratios in China out-licensing history with its $1.25B upfront / $4.8B total Pfizer deal for a bispecific antibody. The company has a diversified portfolio spanning oncology, immunology, and nephrology, with strengths in antibody engineering that attracted Big Pharma attention.
Key Facts
- Pfizer deal: $1.25B upfront on $4.8B total — 26% upfront ratio, highest among 2025 mega-deals
- The high upfront reflects the asset's clinical maturity (Phase II) and Pfizer's competitive urgency
- Diversified revenue base including marketed products in nephrology and oncology
- Antibody engineering platform produced the bispecific that attracted Pfizer's interest
Key Deals
| Partner | Date | Value | Asset |
|---|---|---|---|
| Pfizer | May 2025 | $1.25B upfront / $4.8B total | Bispecific antibody (oncology/immunology) |
Corporate Structure
Hong Kong-listed. Privatized in 2019 and re-listed. Major shareholder: founder Lou Jing (娄竞).